Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8975067 | 1.00 | SLC6A4 (0.66) | SLC6A4HTTSMN1; SMN2TAAR1MAOB | |
| SCHEMBL3822524 | 1.00 | SLC6A4 (0.66) | SLC6A4HTTSMN1; SMN2TAAR1MAOB | |
| Hydrochloric Acid SCHEMBL4102654 | 0.98 | SLC6A4 (0.63) | SLC6A4HTTSMN1; SMN2TAAR1MAOB | |
| SCHEMBL10654362 | 0.89 | SLC6A4 (0.61) | SLC6A4HTTSMN1; SMN2TAAR1MAOB | |
| SCHEMBL879606 | 0.83 | HTT (0.62) | SLC6A4HTTSMN1; SMN2TAAR1MAOB | |
| SCHEMBL9617139 | 0.83 | STAT3 (0.48) | SLC6A4HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL14177156 | 0.83 | SLC6A4 (0.54) | SLC6A4HTTSMN1; SMN2TAAR1MAOB | |
| SCHEMBL9468376 | 0.82 | SLC6A4 (0.89) | SLC6A4TAAR1CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL11806397 | 0.82 | STAT3 (0.47) | SLC6A4HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20394552 | 0.81 | TAAR1 (0.60) | SLC6A4HTTSMN1; SMN2TAAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | UNIV DREXEL (US) | 2025-06-12 | — | — | US | claimed |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2024-03-07 | — | — | US | claimed |
| WO-2023172497-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING COCAINE USE DISORDER | DREXEL UNIVERSITY (US) | 2023-09-14 | — | — | WO | claimed |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2022-07-28 | — | — | US | claimed |
| US-10695302-B2 | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | DREXEL UNIVERSITY (US) | 2020-06-30 | — | — | US | claimed |
| EP-3062791-B1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2020-01-08 | — | — | EP | claimed |
| US-20180092865-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2018-04-05 | — | — | US | claimed |
| US-9861594-B2 | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | DREXEL UNIVERSITY (US) | 2018-01-09 | — | — | US | claimed |
| US-9675565-B2 | D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | DREXEL UNIVERSITY (US) | 2017-06-13 | — | — | US | claimed |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2016-09-08 | — | — | US | claimed |
| WO-2015066019-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2015-05-07 | — | — | WO | claimed |
| US-20140228380-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL (US) | 2014-08-14 | — | — | US | claimed |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL (US) | 2014-08-14 | — | — | US | claimed |
| EP-2603215-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | Philadelphia Health and Education Corporation (US) | 2013-06-19 | — | — | EP | claimed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | claimed |
| EP-1138666-B1 | A preparation method for 4-(P-methoxyphenyl)-2-amino-butane and an insecticidal composition comprising it | COUNCIL SCIENT IND RES (IN) | 2004-03-03 | — | — | EP | claimed |
| US-6441205-B1 | 4-(P-METHOXYPHENYL)-2-AMINOBUTANE EXHIBITING GROWTH INHIBITION AND ANTIFEEDANT ACTIVITY AGAINST LARVAE; INSECTICIDE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-08-27 | — | — | US | claimed |
| US-20020049353-A1 | Synthetic precursors to 4-(P-methoxyphenyl)-2-amino-butane | COUNSEL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-04-25 | — | — | US | claimed |
| EP-1138666-A1 | A preparation method for 4-(P-methoxyphenyl)-2-amino-butane and an insecticidal composition comprising it | Council of Scientific and Industrial Research (IN) | 2001-10-04 | — | — | EP | claimed |
| US-6252114-B1 | TREATING THE ISOLATED PLANT EXTRACT 4-(P-HYDROXYPHENYL)-BUTAN-2-OL WITH MINERAL ACID TO OBTAIN CORRESPONDING PHENOLIC HALIDE, O-METHYLATION OF THE PHENOL, CONVERTING HALIDE TO AZIDE WITH SUBSEQUENT CATALYTIC HYDROGENATION TO AN AMINE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2001-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695302-B2 | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | CHAT, ACHE, SLC18A3 | SLC6A4 23/4885HTT 24/4885SMN1; SMN2 256/4885 |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, COMT, SLC6A2 | SLC6A4 15/4885HTT 31/4885SMN1; SMN2 364/4885 |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | SLC6A4 235/4885HTT 254/4885SMN1; SMN2 657/4885 |
| US-20020049353-A1 | Synthetic precursors to 4-(P-methoxyphenyl)-2-amino-butane | IL4, CASP4, PA2G4 | SLC6A4 2875/4885HTT 4875/4885SMN1; SMN2 1498/4885 |
| US-20140228380-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | DRD3, PARK7, SLC6A3 | SLC6A4 235/4885HTT 254/4885SMN1; SMN2 657/4885 |
| US-20180092865-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | SLC6A4 26/4885HTT 18/4885SMN1; SMN2 255/4885 |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | SLC6A4 26/4885HTT 18/4885SMN1; SMN2 255/4885 |
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | CES2, CHAT, SLC18A2 | SLC6A4 33/4885HTT 1292/4885SMN1; SMN2 1610/4885 |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | DRD3, PARK7, SLC6A3 | SLC6A4 235/4885HTT 254/4885SMN1; SMN2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.